Valuation: Emcure Pharmaceuticals Limited

Market Cap 333B 3.51B 3.13B 2.9B 2.63B 4.94B 5.02B 34.79B 13.67B 174B 13.18B 12.91B 556B P/E 2027 *
28.2x
P/E 2028 * 23x
Enterprise Value 339B 3.58B 3.19B 2.95B 2.68B 5.03B 5.12B 35.45B 13.93B 178B 13.43B 13.16B 566B EV / Sales 2027 *
3.2x
EV / Sales 2028 * 2.76x
Free-Float
22.18%
Yield 2027 *
0.23%
Yield 2028 * 0.27%
10-02 Emcure Pharmaceuticals Limited Receives Income-Tax Department Orders Imposing Aggregate Penalty of INR 577.396732 Million CI
09-23 Emcure Pharmaceuticals Limited Approves Final Dividend for the Financial Year Ended March 31, 2026 CI
09-16 Gilead Sciences Expands Licensing Agreements for HIV Treatment MT
08-06 Emcure Pharmaceuticals Limited, Q1 2027 Earnings Call, Aug 06, 2026
08-06 Emcure Pharmaceuticals Limited Recommends Final Dividend for the Financial Year Ended March 31, 2026 CI
08-06 Emcure Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
08-06 Emcure Pharmaceuticals Limited Announces Board and Management Changes CI
07-21 Emcure Pharmaceuticals Limited Announces Cessation of P.S. Jayakumar as Independent Director and from Board Committees, Effective July 21, 2026 CI
07-20 Emcure Pharmaceuticals Limited completed the acquisition of an additional unknown minority stake in Gennova Biopharmaceuticals Ltd. from Sanjay Singh. CI
07-20 Emcure Pharmaceuticals Limited Expands Use Of Poviztra For MASH Indication Following CDSCO Approval CI
07-12 Emcure Pharmaceuticals Limited executed a share transfer agreement to acquire an additional unknown minority stake in Gennova Biopharmaceuticals Ltd. from its shareholders. CI
07-12 Emcure Pharmaceuticals Limited executed a share transfer agreement to acquire an additional unknown minority stake in Gennova Biopharmaceuticals Ltd. from Sanjay Singh. CI
07-03 Emcure Pharmaceuticals Unit to Acquire Remaining Shares in Canada's Mantra Pharma for C$50 Million MT
1 day-2.97%
1 week-5.46%
Current month-9.08%
1 month-11.84%
3 months-5.08%
6 months+8.21%
Current year+29.47%
1 week 1,746.5
Extreme 1746.5
1,885
1 month 1,746.5
Extreme 1746.5
2,010.3
Current year 1,381
Extreme 1381
2,100.7
1 year 1,306.5
Extreme 1306.5
2,100.7
3 years 889
Extreme 889
2,100.7
5 years 889
Extreme 889
2,100.7
10 years 889
Extreme 889
2,100.7
Manager TitleAgeSince
Chief Executive Officer 75 15/04/1981
Director of Finance/CFO - 30/09/2003
Compliance Officer - 03/02/2026
Director TitleAgeSince
Director/Board Member 73 22/07/2001
Chairman 75 20/09/2026
Director/Board Member 49 27/07/2019
Change 5-day change 1-year change 3-year change Capi.($)
-2.97%-5.46%+28.38% - 3.54B
-1.19%+4.78%+58.40%+119.63% 1,144B
-1.44%+0.60%+33.12%+68.73% 625B
-1.46%+0.71%+23.38%+97.26% 511B
+0.35%+5.42%+39.25%+64.60% 377B
+0.38%+1.13%+70.09%+44.20% 366B
+0.28%+3.44%+21.35%+50.15% 291B
+0.08%+2.47%+1.04%+24.79% 262B
-0.21%+2.59%+45.16%+60.09% 237B
-1.97%-0.13%+23.59%+97.71% 194B
Average -0.77%+5.13%+34.37%+69.68% 401.14B
Weighted average by Cap. -0.72%+6.90%+40.34%+80.94%

Financials

2027 *2028 *
Net sales 106B 1.12B 996M 923M 837M 1.57B 1.6B 11.08B 4.35B 55.5B 4.2B 4.11B 177B 119B 1.26B 1.12B 1.04B 943M 1.77B 1.8B 12.49B 4.9B 62.53B 4.73B 4.63B 199B
Net income 11.89B 126M 112M 104M 93.86M 176M 179M 1.24B 488M 6.22B 471M 461M 19.86B 14.54B 154M 137M 127M 115M 216M 219M 1.52B 597M 7.61B 576M 564M 24.28B
Net Debt 6.38B 67.39M 59.98M 55.59M 50.38M 94.68M 96.26M 667M 262M 3.34B 253M 248M 10.66B -3.28B -34.6M -30.8M -28.55M -25.87M -48.61M -49.43M -343M -135M -1.72B -130M -127M -5.47B
Projected Income Statement - Annual - Emcure Pharmaceuticals Limited
Logo Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and Active Pharmaceutical Ingredient (APIs). It operates across a wide scope of areas, including Gynecology, Cardiovascular, HIV Antivirals, VMN (Vitamins, Minerals & Nutrients), Pain/Analgesics, Nephrology, Oncology, Anti-Infective, Respiratory, CNS. Its brands include Orofer XT and Pause (Gynecological), Proxym (pain), Tenectase (CNS), Vylda (diabetology), Vitanova (VMN). Its API products include S-Amlodipine, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (Tenecteplase), Vintor (Erythropoietin), TENECTASE (Tenecteplase). It has developed two platforms: Mammalian and Microbial.
Employees
6,914
Date Price Change Volume
21/10/26 ₹1,755.10 -0.65% 94,219
19/10/26 ₹1,766.60 -2.97% 108,214
16/10/26 ₹1,820.60 -0.84% 39,565
15/10/26 ₹1,836.00 -1.62% 66,977
14/10/26 ₹1,866.20 -0.13% 157,573
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Emcure Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1,766.60INR
Average target price
2,229.38INR
Spread / Average Target
+26.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Emcure Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. EMCURE Stock